Fabiana Rollini, M.B.Ch.B. (M.D.)

Fabiana Rollini M.B.Ch.B. (M.D.)

Assistant Professor & Medical Director, Cardiovascular Center Inpatient Services (CCU)

Department: Department of Medicine
Business Phone: (904) 244-2060
Business Email: Fabiana.rollini@jax.ufl.edu

Clinical Profile

Specialties
  • Cardiovascular Disease
Languages
  • Speaks English, French and Italian

Publications

2022
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
European heart journal.43(10):959-967[DOI] 10.1093/eurheartj/ehab836.[PMID] 34918066.
2022
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
European heart journal. Cardiovascular pharmacotherapy.8(5):452-461[DOI] 10.1093/ehjcvp/pvab042.[PMID] 34114623.
2022
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention.
Nature reviews. Cardiology.19(12):829-844[DOI] 10.1038/s41569-022-00725-6.[PMID] 35697777.
2022
Patterns and Outcomes of Dual Antiplatelet Therapy Discontinuation After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.15(8):807-809[DOI] 10.1016/j.jcin.2022.02.048.[PMID] 35450680.
2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.
Thrombosis and haemostasis.122(8):1341-1351[DOI] 10.1055/a-1730-8725.[PMID] 34983074.
2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
European heart journal. Cardiovascular pharmacotherapy.8(7):728-737[DOI] 10.1093/ehjcvp/pvac022.[PMID] 35353154.
2022
Reply: The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?
JACC. Cardiovascular interventions.15(2):230-231[DOI] 10.1016/j.jcin.2021.12.002.[PMID] 35057998.
2022
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
European heart journal. Cardiovascular pharmacotherapy.8(7):677-686[DOI] 10.1093/ehjcvp/pvab070.[PMID] 34519777.
2021
Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study.
BMJ open diabetes research & care.9(1):-[DOI] 10.1136/bmjdrc-2020-001939.[PMID] 33637605.
2021
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.
Expert review of clinical pharmacology.14(8):963-978[DOI] 10.1080/17512433.2021.1927709.[PMID] 33993817.
2021
Genotype-Guided Antiplatelet Therapy in Patients With Coronary Artery Disease.
JACC. Cardiovascular interventions.14(7):751-753[DOI] 10.1016/j.jcin.2021.02.005.[PMID] 33744206.
2021
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Lancet (London, England).397(10283):1470-1483[DOI] 10.1016/S0140-6736(21)00533-X.[PMID] 33865495.
2021
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.
JACC. Cardiovascular interventions.14(21):2410-2412[DOI] 10.1016/j.jcin.2021.07.051.[PMID] 34736741.
2021
Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention.
Trends in cardiovascular medicine.():-[DOI] 10.1016/j.tcm.2021.12.007.[PMID] 34936903.
2021
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor.
Journal of thrombosis and thrombolysis.51(3):741-747[DOI] 10.1007/s11239-021-02386-7.[PMID] 33582955.
2020
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Thrombosis and haemostasis.120(1):83-93[DOI] 10.1055/s-0039-1695772.[PMID] 31470444.
2020
Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.
Circulation.142(15):1500-1502[DOI] 10.1161/CIRCULATIONAHA.120.048770.[PMID] 33044856.
2020
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.
Journal of the American Heart Association.9(8):e015865-[DOI] 10.1161/JAHA.120.015865.[PMID] 32306797.
2020
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.
JACC. Basic to translational science.5(5):419-428[DOI] 10.1016/j.jacbts.2020.02.009.[PMID] 32478205.
2019
Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
JACC. Cardiovascular interventions.12(16):1538-1549[DOI] 10.1016/j.jcin.2019.05.028.[PMID] 31377269.
2019
Endocarditis caused by Stenotrophomonas maltophilia-A rare presentation of an emerging opportunistic pathogen.
IDCases.17():e00556-[DOI] 10.1016/j.idcr.2019.e00556.[PMID] 31193238.
2019
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.
JACC. Basic to translational science.4(7):763-775[DOI] 10.1016/j.jacbts.2019.07.011.[PMID] 31998847.
2019
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Circulation.139(14):1661-1670[DOI] 10.1161/CIRCULATIONAHA.118.038317.[PMID] 30630341.
2019
Switching Oral Anticoagulant Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.12(23):2342-2345[DOI] 10.1016/j.jcin.2019.10.017.[PMID] 31806215.
2018
"Malignant" right coronary artery presenting as an ST-segment elevation myocardial infarction-a case report.
Journal of geriatric cardiology : JGC.15(6):467-468[DOI] 10.11909/j.issn.1671-5411.2018.07.001.[PMID] 30108621.
2018
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention.
Nature reviews. Cardiology.15(8):480-496[DOI] 10.1038/s41569-018-0049-1.[PMID] 29973709.
2018
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
Journal of translational medicine.16(1):92-[DOI] 10.1186/s12967-018-1469-8.[PMID] 29642909.
2018
Diabetes and antiplatelet therapy: from bench to bedside.
Cardiovascular diagnosis and therapy.8(5):594-609[DOI] 10.21037/cdt.2018.05.09.[PMID] 30498684.
2018
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy.
Progress in cardiovascular diseases.60(4-5):478-490[DOI] 10.1016/j.pcad.2017.12.004.[PMID] 29291426.
2018
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Clinical pharmacology and therapeutics.104(4):664-674[DOI] 10.1002/cpt.1006.[PMID] 29280137.
2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Circulation.137(23):2450-2462[DOI] 10.1161/CIRCULATIONAHA.118.033983.[PMID] 29526833.
2018
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
Journal of cardiovascular pharmacology and therapeutics.23(1):23-37[DOI] 10.1177/1074248417708617.[PMID] 28565918.
2018
Role of genetic testing in patients undergoing percutaneous coronary intervention.
Expert review of clinical pharmacology.11(2):151-164[DOI] 10.1080/17512433.2017.1353909.[PMID] 28689434.
2018
Standard- and Low-Dose Ticagrelor After Percutaneous Coronary Intervention: Finding the Balance for Patients With Stable Coronary Artery Disease.
Circulation.138(13):1301-1303[DOI] 10.1161/CIRCULATIONAHA.118.036240.[PMID] 30354428.
2018
Syncope in a middle-aged man.
Emergency medicine journal : EMJ.35(6):395-401[DOI] 10.1136/emermed-2017-207381.[PMID] 29784832.
2018
The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts.
Expert review of hematology.11(1):5-12[DOI] 10.1080/17474086.2018.1400378.[PMID] 29091481.
2018
The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACS Patients Undergoing PCI.
Journal of the American College of Cardiology.71(11):1243-1245[DOI] 10.1016/j.jacc.2018.01.040.[PMID] 29544608.
2017
Antithrombotic therapy for patients with STEMI undergoing primary PCI.
Nature reviews. Cardiology.14(6):361-379[DOI] 10.1038/nrcardio.2017.18.[PMID] 28230176.
2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
Thrombosis and haemostasis.117(5):940-947[DOI] 10.1160/TH16-09-0703.[PMID] 28300867.
2017
Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.12(14):1681-1683[DOI] 10.4244/EIJV12I14A276.[PMID] 28216470.
2017
De-Escalation of Platelet P2Y12 Receptor Inhibiting Therapy After Percutaneous Coronary Intervention: Does One Size Fit All?
JACC. Cardiovascular interventions.10(24):2571-2573[DOI] 10.1016/j.jcin.2017.10.007.[PMID] 29268887.
2017
Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y12 Receptor Inhibitors: How Real Is It?
JACC. Cardiovascular interventions.10(2):130-132[DOI] 10.1016/j.jcin.2016.11.021.[PMID] 28104205.
2017
Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus.
Thrombosis and haemostasis.117(1):201-203[DOI] 10.1160/TH16-08-0594.[PMID] 27786340.
2017
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Journal of the American Heart Association.6(4):-[DOI] 10.1161/JAHA.117.005650.[PMID] 28356282.
2017
Institutional profile: University of Florida Health Personalized Medicine Program.
Pharmacogenomics.18(5):421-426[DOI] 10.2217/pgs-2017-0028.[PMID] 28346068.
2017
International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies.
Circulation.136(20):1955-1975[DOI] 10.1161/CIRCULATIONAHA.117.031164.[PMID] 29084738.
2017
In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor-Mediated Signaling in Ticagrelor-Treated Patients.
JACC. Cardiovascular interventions.10(13):1374-1375[DOI] 10.1016/j.jcin.2017.04.027.[PMID] 28683943.
2017
Oral trans-mucosal administration of ticagrelor: is this really the future?
Thrombosis and haemostasis.117(5):826-828[DOI] 10.1160/TH17-03-0177.[PMID] 28331923.
2017
Percutaneous Interventional Repair of an Intraoperative Right Coronary Artery Tear.
JACC. Cardiovascular interventions.10(23):2464-2465[DOI] 10.1016/j.jcin.2017.07.039.[PMID] 29153495.
2017
Reply: Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
Journal of the American College of Cardiology.69(2):250-251[DOI] 10.1016/j.jacc.2016.09.982.[PMID] 28081837.
2017
Switching from ticagrelor to clopidogrel: New answers and further questions.
Thrombosis and haemostasis.117(2):207-208[DOI] 10.1160/TH16-12-0909.[PMID] 28004060.
2017
Switching P2Y12 Receptor Inhibiting Therapies.
Interventional cardiology clinics.6(1):67-89[DOI] 10.1016/j.iccl.2016.08.006.[PMID] 27886824.
2017
The role of oral anticoagulant therapy in patients with acute coronary syndrome.
Therapeutic advances in hematology.8(12):353-366[DOI] 10.1177/2040620717733691.[PMID] 29204262.
2016
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.
European heart journal.37(35):2722-30[DOI] 10.1093/eurheartj/ehv744.[PMID] 26848148.
2016
A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
Expert opinion on drug safety.15(2):275-85[DOI] 10.1517/14740338.2016.1133585.[PMID] 26680584.
2016
Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease.
Circulation journal : official journal of the Japanese Circulation Society.80(4):791-801[DOI] 10.1253/circj.CJ-16-0208.[PMID] 26984587.
2016
Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
Journal of the American College of Cardiology.67(17):1994-2004[DOI] 10.1016/j.jacc.2016.02.045.[PMID] 27012781.
2016
Dual antiplatelet therapy after coronary stenting.
Expert opinion on pharmacotherapy.17(13):1775-87[DOI] 10.1080/14656566.2016.1202924.[PMID] 27309035.
2016
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
Thrombosis and haemostasis.115(3):622-31[DOI] 10.1160/TH15-06-0467.[PMID] 26633836.
2016
Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors.
Thrombosis and haemostasis.116(6):1060-1069[DOI] .[PMID] 27488362.
2016
New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban.
International journal of cardiology.225():154-158[DOI] 10.1016/j.ijcard.2016.09.125.[PMID] 27723533.
2016
Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Circulation.134(11):780-92[DOI] 10.1161/CIRCULATIONAHA.116.023402.[PMID] 27559041.
2016
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
JACC. Cardiovascular interventions.9(11):1089-98[DOI] 10.1016/j.jcin.2016.02.039.[PMID] 27013060.
2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
Journal of the American College of Cardiology.67(10):1145-1154[DOI] 10.1016/j.jacc.2015.12.062.[PMID] 26965534.
2016
Switching P2Y12-receptor inhibitors in patients with coronary artery disease.
Nature reviews. Cardiology.13(1):11-27[DOI] 10.1038/nrcardio.2015.113.[PMID] 26283269.
2016
The Conundrum of Platelet P2Y12 Inhibition in ST-Segment Elevation Myocardial Infarction.
Circulation journal : official journal of the Japanese Circulation Society.80(12):2429-2431[DOI] .[PMID] 27795489.
2016
The Paradox of Smoking and Clopidogrel Effect - Dr Jekyll or Mr Hyde?
Circulation journal : official journal of the Japanese Circulation Society.80(7):1529-31[DOI] 10.1253/circj.CJ-16-0508.[PMID] 27302849.
2016
Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction.
Trends in cardiovascular medicine.26(4):321-34[DOI] 10.1016/j.tcm.2015.08.002.[PMID] 26391344.
2015
[Non-cardiac surgery in patients with previous percutaneous coronary intervention according to the 2014 European guidelines].
Giornale italiano di cardiologia (2006).16(5):277-80[DOI] 10.1714/1870.20424.[PMID] 25994462.
2015
Acute coronary syndromes: applying practice guidelines and defining the unmet need in clinical practice.
The American journal of cardiology.115(5 Suppl):1A-2A[DOI] 10.1016/j.amjcard.2015.01.001.[PMID] 25728970.
2015
Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable patients with CAD treated with dual ANtiplatelet therapy) study.
Journal of thrombosis and thrombolysis.40(3):331-9[DOI] 10.1007/s11239-015-1203-9.[PMID] 25761430.
2015
Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing percutaneous coronary intervention.
Circulation. Cardiovascular interventions.8(6):e002760-[DOI] 10.1161/CIRCINTERVENTIONS.115.002760.[PMID] 26056251.
2015
Drug-drug interactions between clopidogrel and novel cardiovascular drugs.
European journal of pharmacology.765():332-6[DOI] 10.1016/j.ejphar.2015.08.059.[PMID] 26341013.
2015
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
JACC. Cardiovascular interventions.8(11):1457-1467[DOI] 10.1016/j.jcin.2015.02.030.[PMID] 26404199.
2015
Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike.
Progress in cardiovascular diseases.58(3):267-77[DOI] 10.1016/j.pcad.2015.08.009.[PMID] 26277706.
2015
Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
JACC. Cardiovascular interventions.8(8):1075-1083[DOI] 10.1016/j.jcin.2015.02.022.[PMID] 26117466.
2015
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
Future cardiology.11(5):547-64[DOI] 10.2217/fca.15.50.[PMID] 26406386.
2015
Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary intervention.
Journal of the American College of Cardiology.65(16):1714-1715[DOI] 10.1016/j.jacc.2014.12.069.[PMID] 25908082.
2015
Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists.
Journal of thrombosis and thrombolysis.40(1):118-25[DOI] 10.1007/s11239-014-1130-1.[PMID] 25129122.
2014
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
Journal of cardiovascular translational research.7(1):53-63[DOI] 10.1007/s12265-013-9535-3.[PMID] 24395495.
2014
Erratum to: Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Journal of thrombosis and thrombolysis.37(3):358-[DOI] 10.1007/s11239-013-1003-z.[PMID] 24101257.
2014
Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease.
Journal of cardiovascular translational research.7(1):47-52[DOI] 10.1007/s12265-013-9530-8.[PMID] 24357254.
2014
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
Journal of the American College of Cardiology.64(10):1005-14[DOI] 10.1016/j.jacc.2014.06.1170.[PMID] 25190236.
2014
Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery.
Current opinion in cardiology.29(6):553-63[DOI] 10.1097/HCO.0000000000000104.[PMID] 25144343.
2014
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
JACC. Cardiovascular interventions.7(4):426-34[DOI] 10.1016/j.jcin.2013.11.019.[PMID] 24630878.
2014
Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
Journal of thrombosis and thrombolysis.37(2):131-8[DOI] 10.1007/s11239-013-0979-8.[PMID] 23943337.
2014
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Thrombosis and haemostasis.111(2):258-65[DOI] 10.1160/TH13-07-0529.[PMID] 24154863.
2014
Platelet function testing in contemporary clinical and interventional practice.
Current treatment options in cardiovascular medicine.16(5):300-[DOI] 10.1007/s11936-014-0300-y.[PMID] 24652579.
2014
Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.
Vascular health and risk management.10():177-88[DOI] 10.2147/VHRM.S36045.[PMID] 24729713.
2013
Cangrelor: a review on pharmacology and clinical trial development.
Expert review of cardiovascular therapy.11(10):1279-91[DOI] 10.1586/14779072.2013.837701.[PMID] 24138516.
2013
Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation.
Journal of thrombosis and thrombolysis.35(2):155-64[DOI] 10.1007/s11239-012-0846-z.[PMID] 23184484.
2013
Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation.
Thrombosis and haemostasis.110(4):777-84[DOI] 10.1160/TH13-05-0400.[PMID] 23884248.
2013
Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy.
JACC. Cardiovascular interventions.6(2):182-4[DOI] 10.1016/j.jcin.2012.10.007.[PMID] 23428011.
2013
Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus.
Journal of thrombosis and thrombolysis.36(1):14-7[DOI] 10.1007/s11239-012-0828-1.[PMID] 23143668.
2013
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.81(1):42-9[DOI] 10.1002/ccd.24416.[PMID] 22431415.
2013
Platelet function profiles in patients with diabetes mellitus.
Journal of cardiovascular translational research.6(3):329-45[DOI] 10.1007/s12265-013-9449-0.[PMID] 23404189.
2013
Switching from prasugrel to clopidogrel: navigating in unknown waters.
JACC. Cardiovascular interventions.6(2):166-8[DOI] 10.1016/j.jcin.2012.12.001.[PMID] 23428008.
2013
Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.
Therapeutic advances in cardiovascular disease.7(4):197-213[DOI] 10.1177/1753944713487781.[PMID] 23818658.
2012
[The GRAVITAS study].
Giornale italiano di cardiologia (2006).13(1):1-5[DOI] 10.1714/1015.11050.[PMID] 22322466.
2012
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Platelets.23(7):537-51[DOI] .[PMID] 22812566.
2012
Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
Future cardiology.8(4):503-11[DOI] 10.2217/fca.12.35.[PMID] 22871190.
2012
Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus.
Thrombosis and haemostasis.108(5):930-6[DOI] 10.1160/TH12-06-0397.[PMID] 22782352.
2012
Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers.
Journal of thrombosis and thrombolysis.34(3):297-9[DOI] .[PMID] 22923024.
2011
Carotid plaque characterisation by IVUS-VH during carotid stenting: the "eyes wide shut" between plaque morphology and symptoms.
Minerva cardioangiologica.59(6):591-600[DOI] .[PMID] 22134471.
2011
Evaluation of re-endothelization extent at mid-term follow-up after drug eluting balloon plus bare metal stent implantation during primary coronary angioplasty: insight from OCT imaging.
Minerva cardioangiologica.59(1):109-12[DOI] .[PMID] 21285936.
2009
Assessing coronary heart disease in women.
Maturitas.62(3):243-7[DOI] 10.1016/j.maturitas.2008.12.013.[PMID] 19200669.

Office Information

Academic Office
5th Floor, Ambulatory Care Center
655 West 8th Street, C35
Jacksonville, FL 32209
(904) 244-4755
Fabiana.rollini@jax.ufl.edu
Medical Secretary
Monica George
(904) 244-2060
monica.george@jax.ufl.edu

Education

Medical Degree
2007 · University of Modena and Reggio Emilia, Modena, Italy
2012 · University of Modena and Reggio Emilia, Modena, Italy

Multimedia